Costel-George Gherghescu
Research Subjects
Costel-George Gherghescu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Adelina Raluca Marinescu
Department XIII, Discipline of Infectious Diseases, Victor Babes University of Medicine and Pharmacy Timisoara, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
1 shared publication - Adina Chisalita
Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
1 shared publication - Adina-Roxana Mihai
Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
1 shared publication - Adnan Mustafa
Department of Cardiology, “Sf. Apostol Andrei” County Emergency Hospital, 900591 Constanta, Romania
1 shared publication - Alexandra Herlo
Department XIII, Discipline of Infectious Diseases, Victor Babes University of Medicine and Pharmacy Timisoara, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
1 shared publication - Constantin Dina
Faculty of Medicine, Ovidius University, 900527 Constanta, Romania
1 shared publication
Latest Publications
- Open Access
From Daily Pills to Twice-Yearly Protection: A Narrative Review of Long-Acting Cabotegravir and Lenacapavir for HIV Prevention
Oral pre-exposure prophylaxis (PrEP) has been available for more than a decade, yet its population-level impact has been constrained by a single, persistent problem: adherence. Daily pill-taking, even among highly motivated populations, proves difficult to sustain, and the populations with the greatest unmet need for HIV prevention (adolescent girls and young women, transgender individuals, people who inject drugs, and men who have sex with men in the Global South) consistently show the lowest levels of protective drug exposure. Long-acting injectable agents were designed to remove adherence from the daily calculus. Cabotegravir, dosed every eight weeks, demonstrated superiority over daily oral tenofovir/emtricitabine in the phase 3 HPTN 083 and HPTN 084 trials, and lenacapavir, a twice-yearly subcutaneous capsid inhibitor, showed no infections during the primary analysis period of PURPOSE 1 (versus estimated background HIV incidence) and statistically significant superiority over the randomized active comparator F/TDF in PURPOSE 2. Based on a structured search of PubMed, ScienceDirect and ClinicalTrials.gov (January 2010–May 2026) and a tiered appraisal of 77 evidence sources, this narrative review synthesizes evidence on the evolution of PrEP, the pharmacology and clinical performance of cabotegravir and lenacapavir, the pharmacokinetic “tail” phenomenon and its implications for drug resistance and breakthrough infection, diagnostic challenges introduced by long-acting agents, safety and pharmacokinetics in pregnancy and adolescence, stigma and acceptability, and the economics and equity of global access. We also provide a brief overview of the pipeline of next-generation approaches (annual dosing candidates, biodegradable implants, broadly neutralizing antibodies, and multipurpose prevention technologies) that may further reshape HIV prevention over the coming decade; evidence for several of these candidates, particularly broadly neutralizing antibodies, remains early-stage and indirect. Long-acting PrEP is not a panacea; pharmacokinetic tails create resistance-selection windows, diagnostic algorithms must be adapted, and access remains stratified by geography and income. We integrate these findings into an evidence-to-service framework that maps each challenge, across the initiation, maintenance and discontinuation stages of long-acting PrEP use, to its evidence tier, a minimum service requirement for all settings, and adaptations for higher-resource and resource-limited settings. The requirements supported by trial-level evidence are HIV testing at every injection visit with a confirmatory algorithm, planned management of the pharmacokinetic tail with oral bridging, and genotypic resistance testing of every breakthrough infection.
Open AccessFrom Daily Pills to Twice-Yearly Protection: A Narrative Review of Long-Acting Cabotegravir and Lenacapavir for HIV Prevention
Oral pre-exposure prophylaxis (PrEP) has been available for more than a decade, yet its population-level impact has been constrained by a single, persistent problem: adherence. Daily pill-taking, even among highly motivated populations, proves difficult to sustain, and the populations with the greatest unmet need for HIV prevention (adolescent girls and young women, transgender individuals, people who inject drugs, and men who have sex with men in the Global South) consistently show the lowest levels of protective drug exposure. Long-acting injectable agents were designed to remove adherence from the daily calculus. Cabotegravir, dosed every eight weeks, demonstrated superiority over daily oral tenofovir/emtricitabine in the phase 3 HPTN 083 and HPTN 084 trials, and lenacapavir, a twice-yearly subcutaneous capsid inhibitor, showed no infections during the primary analysis period of PURPOSE 1 (versus estimated background HIV incidence) and statistically significant superiority over the randomized active comparator F/TDF in PURPOSE 2. Based on a structured search of PubMed, ScienceDirect and ClinicalTrials.gov (January 2010–May 2026) and a tiered appraisal of 77 evidence sources, this narrative review synthesizes evidence on the evolution of PrEP, the pharmacology and clinical performance of cabotegravir and lenacapavir, the pharmacokinetic “tail” phenomenon and its implications for drug resistance and breakthrough infection, diagnostic challenges introduced by long-acting agents, safety and pharmacokinetics in pregnancy and adolescence, stigma and acceptability, and the economics and equity of global access. We also provide a brief overview of the pipeline of next-generation approaches (annual dosing candidates, biodegradable implants, broadly neutralizing antibodies, and multipurpose prevention technologies) that may further reshape HIV prevention over the coming decade; evidence for several of these candidates, particularly broadly neutralizing antibodies, remains early-stage and indirect. Long-acting PrEP is not a panacea; pharmacokinetic tails create resistance-selection windows, diagnostic algorithms must be adapted, and access remains stratified by geography and income. We integrate these findings into an evidence-to-service framework that maps each challenge, across the initiation, maintenance and discontinuation stages of long-acting PrEP use, to its evidence tier, a minimum service requirement for all settings, and adaptations for higher-resource and resource-limited settings. The requirements supported by trial-level evidence are HIV testing at every injection visit with a confirmatory algorithm, planned management of the pharmacokinetic tail with oral bridging, and genotypic resistance testing of every breakthrough infection.
- Open Access
- 18 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 840
The Role of CT Imaging in a Fractured Coronary Stent with Pseudoaneurysm Formation
We report a case of a 63-year-old male patient with multiple cardiovascular risk factors and previous myocardial infarction who was referred to the emergency department on September 2023 with symptoms and clinical and biological data consistent with an acute coronary event. A coronary angiography revealed severe ostial stenosis of the left anterior descending artery (LAD) and intrastent thrombotic occlusion in the first two segments of the LAD. Two drug-eluting stents were implanted and the patient was discharged when hemodynamically stable; however, three weeks later, he returned to the emergency department complaining of fever, anterior chest pain, dyspnea at rest, and high blood pressure values at home. High levels of troponin T, C-reactive protein, and NT-proBNP were detected and blood cultures showed methicillin-resistant Staphylococcus aureus. The computed tomography (CT) examination showed a saccular dilatation had developed between two fragments of a stent mounted at the level of the LAD, surrounded by a hematic pericardial accumulation. LAD pseudoaneurysm ablation and a double aortocoronary bypass with inverted saphenous vein autograft were performed and the patient showed a favorable postoperative evolution. In this case, surgical revascularization was proven to be the appropriate treatment strategy, demonstrating the need to choose an individualized therapeutic option depending on case-specific factors.
- 18 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 840
Open AccessThe Role of CT Imaging in a Fractured Coronary Stent with Pseudoaneurysm Formation
We report a case of a 63-year-old male patient with multiple cardiovascular risk factors and previous myocardial infarction who was referred to the emergency department on September 2023 with symptoms and clinical and biological data consistent with an acute coronary event. A coronary angiography revealed severe ostial stenosis of the left anterior descending artery (LAD) and intrastent thrombotic occlusion in the first two segments of the LAD. Two drug-eluting stents were implanted and the patient was discharged when hemodynamically stable; however, three weeks later, he returned to the emergency department complaining of fever, anterior chest pain, dyspnea at rest, and high blood pressure values at home. High levels of troponin T, C-reactive protein, and NT-proBNP were detected and blood cultures showed methicillin-resistant Staphylococcus aureus. The computed tomography (CT) examination showed a saccular dilatation had developed between two fragments of a stent mounted at the level of the LAD, surrounded by a hematic pericardial accumulation. LAD pseudoaneurysm ablation and a double aortocoronary bypass with inverted saphenous vein autograft were performed and the patient showed a favorable postoperative evolution. In this case, surgical revascularization was proven to be the appropriate treatment strategy, demonstrating the need to choose an individualized therapeutic option depending on case-specific factors.